Prevalence of autoantibody patterns in a group of patients with early scleroderma

  • Tiziana Guastafierro
  • Francesco Bondanini
  • Antonella Marcoccia
  • Caterina Cimino
  • Bruno Carboni
  • Maria Grazia Modesti
  • Gabriele Valentini
  • Alberto Spanò
Articolo originale



Scleroderma is traditionally classified into two forms with different clinical expression: localized and diffused. An early variant has been described that is distinguished in three different “subsets” characterized by the constant presence of Raynaud phenomenon associated or not with anatomic alterations in the microcirculation detectable by nailfold videocapillaroscopy and/or the presence of autoantibodies (anti centromere or anti topoisomerase I): subset (1): autoantibodies plus microcirculation alterations; subset (2): autoantibodies, in the absence of microcirculation alterations; subset (3): microcirculation alterations, in the absence of autoantibodies.


Our study was conducted on a group of 89 subjects with a positive history for Raynaud’s phenomenon enrolled at the Interdisciplinary Interdepartmental Reference Center for Early Diagnosis of Scleroderma Ulcers (CRIIS) of “Sandro Pertini” hospital in Rome, with the aim of defining the subset to which they belonged basing on the positivity to nailfold videocapillaroscopy and/or the presence of specific autoantibody markers.

Results and conclusions.

We identified: 25 patients with anti-CENP B antibodies, two of which were also positive for anti-SSA antibodies; 7 with anti-Topoisomerase I antibodies, of which one was also positive for anti-SS-A and another for both anti-Ro60 and anti-snRNP. These patients were classified as subset 1 or 2. Three patients were positive for anti-PM/Scl-100 antibodies in addition to other autoantibody markers: one resulted also positive for anti-snRNP, the others for both anti-SS-A and anti-Ro52.


Raynaud phenomenon Systemic sclerosis ANA ENA 



Author Tiziana Guastafierro received a grant to perform the present study from A. Menarini Diagnostics; all other authors declare that they have not received any funding.

Conflicts of interest


Human and animal rights

All procedures involving humans described in the present study have been implemented in accordance with ethical standards of 1964 Helsinki Declaration and subsequent amendments.

Consent form

Informed consent was obtained from all patients included in the study.


  1. 1.
    LeRoy EC, Black C, Fleischmajer R et al. (1998) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205 Google Scholar
  2. 2.
    Mehra S, Walker J, Patterson K et al. (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12:340–354 CrossRefPubMedGoogle Scholar
  3. 3.
    Kayser C, Fritzler MJ (2015) Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol 6:167 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989–2003 CrossRefPubMedGoogle Scholar
  5. 5.
    Valentini G, Marcoccia A, Cuomo G et al. (2014) The concept of early systemic sclerosis following 2013 ACR\(\backslash\)EULAR criteria for the classification of systemic sclerosis. Curr Rheumatol Rev 10:38–44 CrossRefPubMedGoogle Scholar
  6. 6.
    Koenig M, Joyal F, Fritzler MJ et al. (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58:3902–3912 CrossRefPubMedGoogle Scholar
  7. 7.
    Arnett FC (2006) Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 18:579–581 CrossRefPubMedGoogle Scholar
  8. 8.
    Hénault J, Robitaille G, Senécal JL et al. (2006) DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54:963–973 CrossRefPubMedGoogle Scholar
  9. 9.
    Valentini G (2015) Undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). Autoimmun Rev 14:210–213 CrossRefPubMedGoogle Scholar
  10. 10.
    Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5:80–93 PubMedGoogle Scholar
  11. 11.
    Aggarwal R, Lucas M, Fertig N et al. (2009) Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 60:1112–1118 CrossRefPubMedGoogle Scholar
  12. 12.
    Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35–42 CrossRefPubMedGoogle Scholar
  13. 13.
    Tormey VJ, Bunn CC, Denton CP et al. (2001) Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 40:1157–1162 CrossRefGoogle Scholar
  14. 14.
    Walker JG, Pope J, Baron M et al. (2007) The development of systemic sclerosis classification criteria. Clin Rheumatol 26:1401–1409 CrossRefPubMedGoogle Scholar
  15. 15.
    Chang M, Wang RJ, Yangco DT et al. (1998) Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 89:71–78 CrossRefPubMedGoogle Scholar
  16. 16.
    Fanning GC, Welsh KI, Bunn C et al. (1998) HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 37:201–207 CrossRefPubMedGoogle Scholar
  17. 17.
    Harvey GR, Butts S, Rands AL et al. (1999) Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 117:395–402 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hirakata M, Okano Y, Pati U et al. (1993) Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III. J Clin Invest 91:2665–2672 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kuwana M, Kaburaki J, Okano Y et al. (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75–83 CrossRefPubMedGoogle Scholar
  20. 20.
    Okano Y, Steen VD, Medsger TA Jr. (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005–1013 CrossRefPubMedGoogle Scholar
  21. 21.
    Bunn CC, Denton CP, Shi-Wen X et al. (1998) Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 37:15–20 CrossRefPubMedGoogle Scholar
  22. 22.
    Reimer G, Rose KM, Scheer U et al. (1987) Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 79:65–72 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Satoh M, Kuwana M, Ogasawara T et al. (1994) Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. J Immunol 153:5838–5848 PubMedGoogle Scholar
  24. 24.
    Valentini G, Marcoccia A, Cuomo G et al. (2014) Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. Arthritis Care Res (Hoboken) 66:1520–1527 CrossRefGoogle Scholar
  25. 25.
    Valentini G, Marcoccia A, Cuomo G et al. (2013) Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 15:R63 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Gayraud M (2007) Raynaud’s phenomenon. Joint Bone Spine 74:e1–e8 CrossRefPubMedGoogle Scholar
  27. 27.
    Chua-Aguilera CJ, Möller B, Yawalkar N (2017) Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides. Clin Rev Allergy Immunol 53:371–393 CrossRefPubMedGoogle Scholar
  28. 28.
    Pistorius MA, Planchon B, Schott JJ et al. (2006) Heredity and genetic aspects of Raynaud’s disease. J Mal Vasc 31:10–15 CrossRefPubMedGoogle Scholar

Copyright information

© Società Italiana di Patologia Clinica e Medicina di Laboratorio 2018

Authors and Affiliations

  • Tiziana Guastafierro
    • 1
    • 2
  • Francesco Bondanini
    • 2
    • 3
  • Antonella Marcoccia
    • 2
    • 4
  • Caterina Cimino
    • 1
  • Bruno Carboni
    • 1
  • Maria Grazia Modesti
    • 2
    • 4
  • Gabriele Valentini
    • 5
  • Alberto Spanò
    • 1
  1. 1.UOC of Clinical BiochemistrySandro Pertini HospitalRomeItaly
  2. 2.CRIIS (Interdisciplinary, Interdepartmental and Specialistic Reference Center for Early Diagnosis of Scleroderma, Treatment of Sclerodermic Ulcers and Videocapillaroscopy)Sandro Pertini HospitalRomeItaly
  3. 3.UOC of Clinical PathologySaint Eugenio HospitalRomeItaly
  4. 4.UOSD of Ischemic Microangiopathy and Sclerodermic UlcersSandro Pertini HospitalRomeItaly
  5. 5.Rheumatology Unit, Department of Internal and Experimental MedicineUniversity of Campania “Luigi Vanvitelli”NaplesItaly

Personalised recommendations